Madrid and London – 8 October 2018, Aglaris Ltd. today announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
Aglaris is creating transformative technologies to address the key challenges associated with the consistency, scalability and flexibility of manufacturing for allogeneic and autologous cell-based therapies (CBT). The Company has developed a fully autonomous, closed production system that enables the robust and reliable exponential expansion and manufacture of important cell therapies such as T-cells and MSCs (Mesenchymal Stem Cells).
David Horna, co-Founder and COO Aglaris said, “We are pleased to have Steven on board. His extensive experience in innovative tools development and commercialisation will enable us to fast-track the delivery of our unique cell expansion system, Facer, and help the industry to bring these revolutionary therapeutics  to patients around the world.”
Steven Docksey, CEO Aglaris added, “I’m excited to be joining the team at Aglaris as it is poised to revolutionise the manufacture of these vital cell-based therapies. With the explosion in CBT activity in the search for more effective regenerative medicines, being able to address the key industry issues of quality and consistency is imperative.”
Previously, Steven held senior leadership and operational roles with Merck Millipore, Sartorius Stedim and GE Healthcare. Most recently he was adviser and Non-Executive Director at Puridify Ltd and was instrumental its sale to GE Healthcare following strong industry interest. During his career, Steven has been responsible for the successful commercialisation of numerous technology-led tools and technology platforms across the global pharma industry.
David Horna and co-founder Miquel Costa have used their extensive chemical engineering expertise and knowledge of cell culture and bioreactors to create purpose-built tools that enable CBT manufacturers to meet the rigorous GMP / CMC obligations of the pharmaceutical industry. Addressing the key weaknesses in the current methodologies for the manufacture of T-cells and other cell-based therapies has been the key focus of the organisation since its conception five-years ago.
 340 CBT clinical trials in 2012 growing to 990 in 2017 - a CAGR of 24% (Cortelis data - Apr2017); T-cell & MSC therapeutics account for 80% of the 2017 activity & are growing at 40% pa.
About Aglaris Ltd
Aglaris Limited is creating transformative technologies to address key challenges in cell-based therapy bioprocessing. Aglaris’s platform cell expansion technology,the Facer system, aims to bring quality, consistency and scalability to the manufacturing of cell-based therapeutics by enabling the robust GMP / CMC disciplines that are the bedrock of the pharmaceutical industry. Aglaris’s head office and main R&D facilities are located at the Stevenage Bioscience Catalyst, between London and Cambridge, U.K., with additional specialist laboratories at the Tres Cantos Science Park, Madrid, Spain.